Romidepsin
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
Explore 36 assets in Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma →Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Walter Hanel
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04774068CT.gov Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | — | Completed | — | — | — |
NCT04447027CT.gov Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies | — | Completed | — | — | — |
NCT03534180CT.gov Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma | — | Completed | — | — | — |
NCT03278782CT.gov Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | — | Active Not Recruiting | — | — | — |
NCT01897012CT.gov Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | — | Completed | — | — | — |
NCT01742793CT.gov An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) | — | Terminated | — | — | — |
NCT01638533CT.gov Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Romidepsin (this asset) | Walter Hanel | P2 | BB · 65 |
| Etoposide | Alliance for Clinical Trials in Oncology | P4 | BB |
| Cyclophosphamide | City of Hope Medical Center | P2 | BB |
| Dexasone | Zhengzhou University | P4 | BB |
| Prednisone | City of Hope Medical Center | P2 | BB |
| (+)-Vincristine | City of Hope Medical Center | P2 | BB |
| Adriamycin | City of Hope Medical Center | P2 | BB |
| Nivestim | City of Hope Medical Center | P2 | BB |
| Lenalidomide | National Health Research Institutes, Taiwan | P1/2 | BB |
+42 more in the Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma cohort
Other indications for Romidepsin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Burkitt Lymphoma | — | P2 | BBB · 73 |
| Follicular Lymphoma | — | P2 | BBB · 73 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P3 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Romidepsin in Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/romidepsin-mature-t-cell-and-nk-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →